Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin
- PMID: 20683949
- DOI: 10.1002/hep.23669
Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin
Abstract
Antidiabetic thiazolidinediones (TZD) have in vitro antiproliferative effect in epithelial cancers, including hepatocellular carcinoma (HCC). The effective anticancer properties and the underlying molecular mechanisms of these drugs in vivo remain unclear. In addition, the primary biological target of TZD, the ligand-dependent transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma), is up-regulated in HCC and seems to provide tumor-promoting responses. The aim of our study was to evaluate whether chronic administration of TZD may affect hepatic carcinogenesis in vivo in relation to PPARgamma expression and activity. The effect of TZD oral administration for 26 weeks was tested on tumor formation in PPARgamma-expressing and PPARgamma-deficient mouse models of hepatic carcinogenesis. Proteomic analysis was performed in freshly isolated hepatocytes by differential in gel electrophoresis and mass spectrometry analysis. Identified TZD targets were confirmed in cultured PPARgamma-deficient hepatocytes. TZD administration in hepatitis B virus (HBV)-transgenic mice (TgN[Alb1HBV]44Bri) reduced tumor incidence in the liver, inhibiting hepatocyte proliferation and increasing apoptosis. PPARgamma deletion in hepatocytes of HBV-transgenic mice (Tg[HBV]CreKOgamma) did not modify hepatic carcinogenesis but increased the TZD antitumorigenic effect. Proteomic analysis identified nucleophosmin (NPM) as a TZD target in PPARgamma-deficient hepatocytes. TZD inhibited NPM expression at protein and messenger RNA levels and decreased NPM promoter activity. TZD inhibition of NPM was associated with the induction of p53 phosphorylation and p21 expression.
Conclusion: These findings suggest that chronic administration of TZD has anticancer activity in the liver via inhibition of NPM expression and indicate that these drugs might be useful for HCC chemoprevention and treatment.
Similar articles
-
Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro.Hepatology. 2010 Jun;51(6):2008-19. doi: 10.1002/hep.23550. Hepatology. 2010. PMID: 20512989
-
The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.Int J Oncol. 2010 Jan;36(1):223-31. Int J Oncol. 2010. PMID: 19956851
-
Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.Hepatology. 2006 Jan;43(1):134-43. doi: 10.1002/hep.20994. Hepatology. 2006. PMID: 16374840
-
Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.Endocr Relat Cancer. 2006 Jun;13(2):401-13. doi: 10.1677/erc.1.01182. Endocr Relat Cancer. 2006. PMID: 16728570 Review.
-
Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios.World J Gastroenterol. 2022 Jul 28;28(28):3535-3554. doi: 10.3748/wjg.v28.i28.3535. World J Gastroenterol. 2022. PMID: 36161051 Free PMC article. Review.
Cited by
-
Avicularin ameliorates human hepatocellular carcinoma via the regulation of NF‑κB/COX‑2/PPAR‑γ activities.Mol Med Rep. 2019 Jun;19(6):5417-5423. doi: 10.3892/mmr.2019.10198. Epub 2019 Apr 25. Mol Med Rep. 2019. PMID: 31059053 Free PMC article.
-
Isoforms of the orphan nuclear receptor COUP‑TFII differentially modulate pancreatic cancer progression.Int J Oncol. 2022 May;60(5):55. doi: 10.3892/ijo.2022.5345. Epub 2022 Mar 29. Int J Oncol. 2022. PMID: 35348189 Free PMC article.
-
Clustering nuclear receptors in liver regeneration identifies candidate modulators of hepatocyte proliferation and hepatocarcinoma.PLoS One. 2014 Aug 12;9(8):e104449. doi: 10.1371/journal.pone.0104449. eCollection 2014. PLoS One. 2014. PMID: 25116592 Free PMC article.
-
Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.Oncologist. 2013;18(2):148-56. doi: 10.1634/theoncologist.2012-0302. Epub 2013 Jan 23. Oncologist. 2013. PMID: 23345544 Free PMC article.
-
MiR-27a promotes hepatocellular carcinoma cell proliferation through suppression of its target gene peroxisome proliferator-activated receptor γ.Chin Med J (Engl). 2015 Apr 5;128(7):941-7. doi: 10.4103/0366-6999.154302. Chin Med J (Engl). 2015. PMID: 25836616 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous